| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8446408 | European Journal of Cancer | 2012 | 7 Pages |
Abstract
Patients with GNBn tumours are rare and have a very heterogeneous outcome. Except for LDH and MKI, the factors prognostic in the overall NB cohort are also prognostic in patients with GNBn. Similar to the overall NB cohort, patients with GNBn older than 18 months of age, with stage 4 disease represent a high-risk sub-group and should be considered for aggressive treatment upfront.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Paola Angelini, Wendy B. London, Susan L. Cohn, Andrew D.J. Pearson, Katherine K. Matthay, Tom Monclair, Peter F. Ambros, Hiroyuki Shimada, Ivo Leuschner, Michel Peuchmaur, Meredith S. Irwin, Sylvain Baruchel,